FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103058588> ?p ?o ?g. }

• W2103058588 endingPage "300" @default.
• W2103058588 startingPage "291" @default.
• W2103058588 abstract "Purpose To investigate whether there is any correlation between standard efficacy endpoints—specifically, tumor response, progression-free survival, and overall survival—and tumor perfusion parameters measured by using dynamic contrast material–enhanced ultrasonography (US) in patients with advanced hepatocellular carcinoma (HCC) treated with bevacizumab. Materials and Methods The institutional review board approved the study, and all patients provided written informed consent before their enrollment. Between June 3, 2005, and September 28, 2007, 42 patients (33 men, nine women; median age, 62 years; age range, 23–84 years) participated in this phase II study of single-agent bevacizumab treatment. Tumor response (based on RECIST [response evaluation criteria in solid tumors]) at 2 months was assessed in 37 patients, and progression-free survival and overall survival were assessed in all 42 patients. Dynamic contrast-enhanced US (ie, dynamic US) was performed before treatment (day 0); on days 3, 7, 14, and 60 after treatment; and every 2 months thereafter. Tumor perfusion parameters were estimated quantitatively from contrast material uptake curves constructed from raw linear data. The changes in dynamic US functional parameters between day 0 and the later time points were compared between treatment responders and nonresponders by using nonparametric tests. Given multiple comparisons, P < .001 indicated significance. Results The percentage decrease in several dynamic US parameters between day 0 and day 3 showed trends toward correlation with (a) tumor response in terms of total area under the time-intensity curve (AUC) (P = .02), AUC during wash in (P = .04), AUC during washout (P = .02), and time to peak intensity (P = .03); (b) progression-free survival in terms of time to peak intensity (P = .028); and (c) overall survival in terms of AUC (P = .002) and AUC during washout (P = .003). Conclusion Dynamic US can be used to quantify dynamic changes in tumor vascularity as early as 3 days after bevacizumab administration in patients with HCC. These early changes in tumor perfusion may be predictive of tumor response at 2 months, progression-free survival, and overall survival, and they may be potential surrogate measures of the effectiveness of antiangiogenic therapy in patients with HCC. © RSNA, 2010 Supplemental material: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.10091870/-/DC1" @default.
• W2103058588 created "2016-06-24" @default.
• W2103058588 creator A5017132355 @default.
• W2103058588 creator A5026485141 @default.
• W2103058588 creator A5034548258 @default.
• W2103058588 creator A5041492973 @default.
• W2103058588 creator A5056075131 @default.
• W2103058588 creator A5063475902 @default.
• W2103058588 creator A5069704782 @default.
• W2103058588 creator A5078396210 @default.
• W2103058588 creator A5085121407 @default.
• W2103058588 date "2011-01-01" @default.
• W2103058588 modified "2023-10-18" @default.
• W2103058588 title "Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantification—Preliminary Results" @default.
• W2103058588 cites W1583635506 @default.
• W2103058588 cites W1974956292 @default.
• W2103058588 cites W1980780250 @default.
• W2103058588 cites W1998953784 @default.
• W2103058588 cites W2015540824 @default.
• W2103058588 cites W2037082631 @default.
• W2103058588 cites W2041221441 @default.
• W2103058588 cites W2051159146 @default.
• W2103058588 cites W2051525992 @default.
• W2103058588 cites W2062603022 @default.
• W2103058588 cites W2071266566 @default.
• W2103058588 cites W2076668534 @default.
• W2103058588 cites W2080663543 @default.
• W2103058588 cites W2083246937 @default.
• W2103058588 cites W2087837938 @default.
• W2103058588 cites W2101864834 @default.
• W2103058588 cites W2113278065 @default.
• W2103058588 cites W2136977965 @default.
• W2103058588 cites W2139248078 @default.
• W2103058588 cites W2153935627 @default.
• W2103058588 cites W2156012497 @default.
• W2103058588 cites W2158547045 @default.
• W2103058588 cites W2164983910 @default.
• W2103058588 cites W2165405350 @default.
• W2103058588 cites W2167290534 @default.
• W2103058588 cites W2167805334 @default.
• W2103058588 cites W2211426564 @default.
• W2103058588 cites W2224059765 @default.
• W2103058588 cites W2266266292 @default.
• W2103058588 cites W2321878150 @default.
• W2103058588 cites W2532302040 @default.
• W2103058588 cites W2591170673 @default.
• W2103058588 doi "https://doi.org/10.1148/radiol.10091870" @default.
• W2103058588 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20980447" @default.
• W2103058588 hasPublicationYear "2011" @default.
• W2103058588 type Work @default.
• W2103058588 sameAs 2103058588 @default.
• W2103058588 citedByCount "202" @default.
• W2103058588 countsByYear W21030585882012 @default.
• W2103058588 countsByYear W21030585882013 @default.
• W2103058588 countsByYear W21030585882014 @default.
• W2103058588 countsByYear W21030585882015 @default.
• W2103058588 countsByYear W21030585882016 @default.
• W2103058588 countsByYear W21030585882017 @default.
• W2103058588 countsByYear W21030585882018 @default.
• W2103058588 countsByYear W21030585882019 @default.
• W2103058588 countsByYear W21030585882020 @default.
• W2103058588 countsByYear W21030585882021 @default.
• W2103058588 countsByYear W21030585882022 @default.
• W2103058588 countsByYear W21030585882023 @default.
• W2103058588 crossrefType "journal-article" @default.
• W2103058588 hasAuthorship W2103058588A5017132355 @default.
• W2103058588 hasAuthorship W2103058588A5026485141 @default.
• W2103058588 hasAuthorship W2103058588A5034548258 @default.
• W2103058588 hasAuthorship W2103058588A5041492973 @default.
• W2103058588 hasAuthorship W2103058588A5056075131 @default.
• W2103058588 hasAuthorship W2103058588A5063475902 @default.
• W2103058588 hasAuthorship W2103058588A5069704782 @default.
• W2103058588 hasAuthorship W2103058588A5078396210 @default.
• W2103058588 hasAuthorship W2103058588A5085121407 @default.
• W2103058588 hasConcept C126322002 @default.
• W2103058588 hasConcept C126838900 @default.
• W2103058588 hasConcept C141071460 @default.
• W2103058588 hasConcept C141341695 @default.
• W2103058588 hasConcept C143409427 @default.
• W2103058588 hasConcept C143998085 @default.
• W2103058588 hasConcept C2776694085 @default.
• W2103058588 hasConcept C2777106319 @default.
• W2103058588 hasConcept C2777802072 @default.
• W2103058588 hasConcept C2778019345 @default.
• W2103058588 hasConcept C2779984678 @default.
• W2103058588 hasConcept C2989005 @default.
• W2103058588 hasConcept C2994142346 @default.
• W2103058588 hasConcept C31760486 @default.
• W2103058588 hasConcept C535046627 @default.
• W2103058588 hasConcept C71924100 @default.
• W2103058588 hasConcept C76318530 @default.
• W2103058588 hasConceptScore W2103058588C126322002 @default.
• W2103058588 hasConceptScore W2103058588C126838900 @default.
• W2103058588 hasConceptScore W2103058588C141071460 @default.
• W2103058588 hasConceptScore W2103058588C141341695 @default.
• W2103058588 hasConceptScore W2103058588C143409427 @default.
• W2103058588 hasConceptScore W2103058588C143998085 @default.
• W2103058588 hasConceptScore W2103058588C2776694085 @default.

• next